Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer
sPD-L1 is easily detectable in the plasma of EC patients and may be associated with aggressive clinical features and PD-L1-expressing immune cells infiltrating the tumor stroma. sPD-L1 plasma levels in EC patients undergoing immunotherapy can be further tested as a biomarker for therapeutic stratification.
Authors
- Grigorios Trypsianis (ORCID: https://orcid.org/0000-0002-2544-1721)
- Achilleas Mitrakas (ORCID: https://orcid.org/0000-0002-9980-7773)
- Panagiotis Tsikouras (ORCID: https://orcid.org/0000-0002-9495-4424)
- Alexandra Giatromanolaki (ORCID: https://orcid.org/0000-0003-3706-8845)
- Konstantinos Nikolettos (ORCID: https://orcid.org/0000-0001-8291-5375)
- Antonios Koutras (ORCID: https://orcid.org/0000-0002-7229-9983)
- Emmanuel N. Kontomanolis
- Michael Koukourakis
- Nikolaos Nikolettos
Institutions
- Democritus University of Thrace (GR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21873/anticanres.17378
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.17